Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Efficacy-safety trade-off and patient selection: A meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies

Efficacy and safety of CAR-T cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A propensity score-matched analysis

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

CAR T-Cell Therapy Resource Center

Interview with Laura R. Dickinson, PA-C: The Community Perspective—Getting Patients to CAR-T

Leukemia and Lymphoma Society: CAR T-Cell Therapy

What is CAR T Cell Therapy?

ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

International Journal of Hematology

Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy

Frontiers in Immunology

Efficacy-safety trade-off and patient selection: A meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL

Science Immunology

Genomic correlates of clinical CAR T cell activity

Technology in Cancer Research and Treatment

Leveraging immunotherapy in acute myeloid leukemia treatment: Opportunities and challenges

International Immunopharmacology

Advancing chimeric antigen receptor T-cell therapy frontiers in glioblastoma: Navigating the current landscape from clinical hurdles to breakthrough strategies

European Journal of Nuclear Medicine and Molecular Imaging

Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: A DESCAR-T study

Cancers (Basel)

Geriatric assessment in patients aged 70 years and older considered for CAR T-cell therapy: A retrospective study

Cancers (Basel)

Efficacy and safety of CAR-T cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A propensity score-matched analysis

Transplantation and Cellular Therapy

Long-Term follow-up of CD19 CAR-T for R/R B-NHL: Ki-67 as a prognostic factor for sustained remission

Transplantation and Cellular Therapy

Chimeric antigen receptor T-Cell therapy in autoimmune disorders: An expert panel opinion from the American Society for Transplantation and Cellular Therapy

ICANS or TIAN? Neurologic Toxicity Following CAR T-Cell Therapy in a Patient With Primary Central Nervous System Lymphoma

Identifying CRS in Patients Who Underwent CAR T-Cell Infusion

Cytopenias After CAR T-cell Therapy: Varying Predictive Markers, Duration

Fast Facts #12: BCMA Targets